Last reviewed · How we verify
NCT03945864
Antimicrobial Synthetic Bone Grafts
Phase 1, PHASE2 trial testing antimicrobial synthetic bone graft in Bone Infection in 12 participants. Completed in 15 August 2021.
1 September 2020
Quick facts
| Lead sponsor | Eskisehir Osmangazi University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 June 2019 |
| Primary completion | 1 September 2020 |
| Estimated completion | 15 August 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- antimicrobial synthetic bone graft
- parentaral antimicrobials and pure bone grafts
Conditions studied
- Bone Infection — all drugs for Bone Infection →
- Bone Graft Infection — all drugs for Bone Graft Infection →
Sponsor
Eskisehir Osmangazi University
Who can join
Adults 18 to 90, any sex, with Bone Infection or Bone Graft Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to produce synthetic bone tissue graft that supports bone regeneration and combats infection simultaneously, according to industry standards and regulations. This original and high value added biomaterial "silver doped calcium phosphate based synthetic bone tissue " will be used in clinical trials in patients with osteomyelitis and implant-related infections for the treatment. Chronic bone infections are one of the most important problems in orthopedic surgery and are not just a problem of developed societies. When open fracture cases, which may get infected in 1-50%, implant-related infections and diabetic foot ulcer cases are taken into consideration, osteomyelitis will be seen as a very common problem all over the world. Multiple surgeries, long-term use of antibiotics and the high costs affects all societies. The use of synthetic bone grafts is growing faster than the natural bone grafts in the world. USA has spent 246 million US dollars for the use of synthetic bone graft in 2010. For the treatment of bone infections antibiotic impregnated synthetic bone grafts with different characteristics are used. Although these antibiotic impregnated synthetic bone grafts are superior compared to antibiotic bone cement with the implementation of different antibiotics and to be absorbable but they cannot show optimum benefit because the release of antibiotics is not due to host matrix degradation but diffusion control. The other issue to be considered as this regard that the development of microbial resistance to these antibiotics which is also a serious problem. Innovative synthetic bone graft with better contribution of the needs of mechanical properties, depending on the applied bone region, optimized antimicrobial activity and bone tissue regeneration are needed. In this study, it will be determined whether this silver ion -doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids that may occur in chronic bone infection during disease process or after surgical debridement, also has the capacity to treat the infection in the bone will be used in 12 patients who had been diagnosed as chronic osteomyelitis to see if it cause any unwanted side effect in normal usage conditions and generates unacceptable risks. Clinical, laboratory and radiological investigations will be used to demonstrate the healing of the infections and the cavities in the bone. Blood and urine levels of silver will be detected from patients. Antimicrobial activity of silver is well-known. The effectiveness of the silver and potential toxicity is related to the dose of silver and application form. In orthopedics, the use of silver is mostly limited to elemental silver coating of metal implants. There is no biotechnologic approach manufactured silver ion -doped calcium phosphate -based synthetic bone graft in the health sector yet. Ionic silver has advantages such as low toxicity, no tolerance of silver against bacteria, and strong antibacterial activity. The trapping of silver ions in the calcium phosphate based ceramic structure overcomes the other systems with its controlled release and its ability to be effective at minimum doses. The project is an original work since it will contribute to bone regeneration while at the same time removing the infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Early Clinical Experience with Silver-Ion Doped Synthetic Bone Grafts for the Treatment of Chronic Bone Infections: A Retrospective Study.
Yücel B, Köse AA, Köse N. · · 2025 · PMID 41517279 · DOI 10.3390/jcm15010029
Verify or expand the search:
- PubMed search for NCT03945864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bone Infection
Currently open trials in the same condition.
- NCT05883995 — Avis-PHAGEinLYON Clinic · recruiting
Other Eskisehir Osmangazi University trials
Trials by the same sponsor.
- NCT07343505 — Environmental Enrichment Intervention and Brain Development in Preterm Infants · NA · not yet recruiting
- NCT07346963 — RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV · not yet recruiting
- NCT07342101 — Evaluating the LGG of on Acute Infectious Diarrhea in Children · NA · not yet recruiting
- NCT07307924 — The Effect of Motivational Interviewing on Knowledge, Self-Efficacy, and Treatment Adherence in Patients With Primary Hy · NA · enrolling by invitation
- NCT07131267 — Evaluating Sexual Functioning in Trans Men During the Gender Affirmation Process: A Mixed Methods Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03945864 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eskisehir Osmangazi University
- Last refreshed: 29 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03945864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing